Search
DYNE-251
go.drugbank.com/drugs/DB18130InvestigationalIt is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping. … DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1).
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Lanabecestat
go.drugbank.com/drugs/DB14814InvestigationalLanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).
BP-14979
go.drugbank.com/drugs/DB16302InvestigationalBP-14979 is under investigation in clinical trial NCT01785147 (Efficacy and Safety of BP1.4979 in Smoking Cessation).
KRN-5500
go.drugbank.com/drugs/DB15215InvestigationalKRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Oplunofusp
go.drugbank.com/drugs/DB15313InvestigationalDAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).
Apratastat
go.drugbank.com/drugs/DB13020InvestigationalTmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).
Sonpiretigene isteparvovec
go.drugbank.com/drugs/DB17844InvestigationalDeveloped by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). … Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy.
Synonyms: vMCO-IPegapamodutide
go.drugbank.com/drugs/DB14817InvestigationalPegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants).